Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $22.50, for a total transaction of $22,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.97, for a total value of $55,152.50.
• On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.72, for a total value of $346,080.00.
• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.25, for a total value of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.

Enliven Therapeutics Trading Down 0.9 %

Shares of Enliven Therapeutics stock opened at $24.49 on Thursday. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $26.00. The firm has a fifty day simple moving average of $17.82 and a 200-day simple moving average of $14.96. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -11.18 and a beta of 1.05.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. As a group, research analysts predict that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Mizuho began coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price target for the company.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after acquiring an additional 1,029 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Enliven Therapeutics by 17.8% in the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after buying an additional 2,041 shares during the last quarter. AJOVista LLC acquired a new position in Enliven Therapeutics during the 4th quarter worth about $28,000. Exchange Traded Concepts LLC increased its position in Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after acquiring an additional 2,208 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Enliven Therapeutics by 67.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.